			Home About us Contact

Bag Systems (bag + system)

Distribution by Scientific Domains

Medical Sciences	100%

Selected Abstracts

Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems

HAEMOPHILIA, Issue 5 2008
T. BURNOUF
Summary., Cryoprecipitate is still used to treat factor VIII (FVIII), von Willebrand factor (VWF) and/or fibrinogen deficiency. Recently a solvent-detergent (S/D) process of minipools of cryoprecipitate performed in a closed bag system has been designed to improve its viral safety. Still, cryoprecipitate has other drawbacks, including low concentration in active proteins, and presence of haemolytic isoagglutinins. We report here the biochemical evaluation of S/D-treated minipools of cryoprecipitates depleted of cryo-poor plasma. Cryoprecipitates were solubilized by 8 mL of a sterile glucose/saline solution, pooled in batches of 40 donations and subjected to S/D treatment in a plastic bag system using either 2% TnBP or 1% TnBP-1%Triton X-45, followed by oil extractions (n = 10). Mean (±SD) FVIII and fibrinogen content was 8.86 (±1.29) IU mL,1 and 16.02 (±1.98) mg mL,1, and 8.92 (±1.05) IU mL,1 in cryoprecipitate minipools treated with 2% TnBP, and 17.26 (±1.71) mg mL,1, in those treated by TnBP-Triton X-45, respectively. The WWF antigen, ristocetin cofactor and collagen binding activities were close to 10, 7 and 8 IU mL,1, respectively, and were not affected by either SD treatment. VWF multimeric pattern of SD-treated cryoprecipitates were similar to that of normal plasma, and the >15 mers and >10 mers content was identical to that of the starting cryoprecipitates. The anti-A and anti-B titre was 0,1 and 0,1/8, respectively. Therefore, it is possible to prepare virally inactivated cryoprecipitate minipools depleted of isoagglutinins and enriched in functional FVIII, VWF and clottable fibrinogen. [source]

Flush volumes delivered from pressurized bag pump flush systems in neonates and small children

PEDIATRIC ANESTHESIA, Issue 8 2002
Anita Cornelius MD
SummaryBackground: The aim of this study was to measure the volumes of fluid delivered with a fast flush bolus from a flow regulating device. Methods: In-vitro fast flush bolus volumes, the volumes delivered from a bag pump flush system while opening the flow regulating device for 1, 2 or 5 s, were gravimetrically measured through a 22-G and a 24-G cannula. In-vivo 1- and 2-s fast flush bolus volumes and the volume required to purge the tubing between stopcock and arterial cannula from visible blood after blood sampling were recorded in 12 anaesthetized neonates and infants (mean age 2.17 ± 1.97 months, range 0.26,5.37 months) with a 24-G radial arterial cannula by continuously weighing the bag pump flush system at manometer pressures of 100, 200 and 300 mmHg. Results: In-vitro fast flush bolus volumes ranged from 0.23 ± 0.04 ml (1-s , 100 mmHg, 24-G cannula) to 2.95 ± 0.38 ml (5-s, 300 mmHg, 22-G cannula). Volumes were larger using a 22-G cannula than a 24-G cannula (P < 0.01) and increased with longer flushing periods (P < 0.0001) and higher manometer pressures (P < 0.0001). In-vivo 1- and 2-s fast flush bolus volumes correlated well with driving pressures (infusion pressure minus mean arterial pressure) (r2 = 0.81/0.72). 1-s fast flush bolus volumes delivered (ml) were 0.0025 × mmHg driving pressure and 2-s fast flush bolus volumes delivered (ml) were 0.0043 × mmHg driving pressure. The mean volume delivered to purge blood from the arterial pressure tubing was 0.94 ± 0.18 ml (range 0.61,1.34 ml). Conclusions: Fast bolus flushing from pressurized infusion bag systems, using the flow regulating device tested, can be applied during neonatal and paediatric anaesthesia without delivering uncontrolled amounts of fluid. [source]

4245: Non-surgical strategies for PCO prevention

ACTA OPHTHALMOLOGICA, Issue 2010
IM WORMSTONE
Purpose Surgical approaches and IOL design have gone some way to reduce the rate of PCO progression. Despite these efforts PCO remains a common and important problem which diminishes the visual quality of patients and is a major financial burden on healthcare providers. If we are to effectively respond to the problem of PCO then a biological solution has to be adopted to reduce/prevent formation of light scattering changes. Methods Methods have been employed to investigate PCO development, which include in vitro cell culture and capsular bag models; in vivo animal models and post-mortem analysis. These have greatly aided our understanding of PCO. Results A number of basic approaches have been identified to prevent PCO. 1) To kill the entire lens epithelial population. This will require a pharmacological agent, therefore delivery of this drug needs to be localised to the target cells, but have limited access to non-target cells; closed capsular bag systems such as perfect capsule provides opportunity to achieve this aim. 2) Maintenance of a cell monolayer on the posterior capsule. In particular the role of TGF, has been investigated, which is known to cause matrix deformation. Disruption of TGF, signalling pathways can suppress matrix deformation and thus reduce light scatter. 3) Recreation of a lens is the ultimate solution. While it has been shown that lens fibre differentiation can be promoted in animal systems, perfect formation of the lens is not achieved and the protein density is typically low relative to the native lens. Conclusion Strategies to prevent PCO are being actively developed, which will are greatly aided by improved drug delivery systems. The development of biological/pharmacological approaches in concert with improved surgical methods and IOL designs should yield benefit to patients. Commercial interest [source]